Sanofi S.A., FR0000120578

Sanofi stock gains 1.02 percent as antibody deal advances pipeline

Published on 10/07/2026 at 14:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock traded at EUR 71.33 on October 7, 2026, after its Regeneron alliance added four long-acting antibody candidates. Q2 sales rose 17.8 percent to EUR 11.6 billion.

Bauhaus geometric poster with abstract stylized molecular structure in violet and cyan on white background with bold sans-serif PHARMACIE PARIS text — Sanofi FR0000120578 Bauhaus-style poster with abstract molecular structure in violet-cyan-white reading PHARMACIE PARIS, Illustration mit AI erstellt.

Sanofi (ISIN FR0000120578) was trading at EUR 71.33 on Euronext Paris on October 7, 2026 at 1:49 p.m. CEST, up 1.02 percent from the prior close. The move follows an expanded Regeneron alliance that adds four long-acting antibody candidates to Sanofi's immunology pipeline.

Alliance adds four antibody programs

On October 1, 2026, Sanofi and Regeneron expanded their global collaboration around next-generation treatments for type 2 inflammation, according to Sanofi. The additions include a clinical-stage IL-13 antibody, an IL-4xIL-13 bispecific antibody and two preclinical candidates.

The financial structure is substantial but staged. Sanofi will pay USD 1 billion upfront, while additional milestone payments can reach USD 7 billion; the companies will share development and commercialization costs and future profits equally, Sanofi said. That split limits Sanofi's exposure compared with a wholly owned program, while the milestone portion remains tied to development, regulatory and commercial outcomes.

Q2 growth raises the bar

Sanofi's Q2 2026 net sales increased 17.8 percent year over year to EUR 11.6 billion, while business EPS rose 33.3 percent, according to ScanX. The same report said the business operating income margin expanded by 3.8 percentage points, giving investors a sharper operating comparison than revenue alone.

That performance sets a demanding benchmark for the next report. Sanofi's latest investor release states that its Q3 2026 results will be published on October 30, 2026, with management presenting the figures during a webcast, Sanofi announced on October 6, 2026.

Analysts keep a neutral balance

For the US-listed ADR coverage, Gekko reports one Buy and three Hold ratings from four firms, with an average 12-month target of USD 53.72, a low of USD 49 and a high of USD 62, Gekko reported on October 6, 2026. The consensus range shows that analysts see upside in the ADR, but the spread between USD 49 and USD 62 also reflects differing assumptions about pipeline execution.

Sanofi stock trades above prior close

Sanofi stock was trading at EUR 71.33 on Euronext Paris on October 7, 2026 at 1:49 p.m. CEST, with a session range of EUR 70.51 to EUR 71.44 and volume of 355,995 shares. Its market capitalization was EUR 85.6 billion, while the 52-week range stood at EUR 69.75 to EUR 91.15.